Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Boston Scientific ( (BSX) ) has shared an announcement.
On August 29, 2025, Boston Scientific announced that Jeffrey B. Mirviss will retire from his position as Executive Vice President and President of Peripheral Interventions, effective December 1, 2025. He will continue as a senior advisor until February 27, 2026, receiving a prorated base salary. The company plans to enter into a Retirement Agreement with Mr. Mirviss, ensuring he receives benefits consistent with the company’s Executive Retirement Plan and other incentive programs.
The most recent analyst rating on (BSX) stock is a Buy with a $116.00 price target. To see the full list of analyst forecasts on Boston Scientific stock, see the BSX Stock Forecast page.
Spark’s Take on BSX Stock
According to Spark, TipRanks’ AI Analyst, BSX is a Outperform.
Boston Scientific’s strong financial performance and positive earnings call outlook are significant strengths, driving the overall score. However, the high valuation and neutral technical indicators temper the score. The company’s strategic growth initiatives and robust segment performance support a positive long-term outlook, despite some near-term valuation concerns.
To see Spark’s full report on BSX stock, click here.
More about Boston Scientific
Boston Scientific is a leading company in the medical device industry, specializing in the development and manufacturing of a wide range of products used in interventional medical specialties. The company focuses on providing innovative solutions for various medical conditions, enhancing patient care and improving clinical outcomes.
Average Trading Volume: 7,221,032
Technical Sentiment Signal: Buy
Current Market Cap: $158B
For detailed information about BSX stock, go to TipRanks’ Stock Analysis page.